Ceftriaxone and ciprofloxacin restriction in an intensive care unit: Less incidence of Acinetobacter spp. and improved susceptibility of Pseudomonas aeruginosa

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 30, Issue 6, 2011, Pages 603-609

  Presentado, Julio César Medina ^a   López, Daniela Paciel ^a   Castiglioni, Maximiliano Berro ^b   Gerez, Jorge ^b  

^a DEPARTAMENTO DE BIOQUÍMICA   (Uruguay)

^b Hospital Policial   (Uruguay)

Author keywords

Acinetobacter baumannii; Antibacterial agents; Drug resistance, multiple; Pseudomonas aeruginosa; Uruguay

Indexed keywords

CEFTRIAXONE; CIPROFLOXACIN;

ANTIBIOTIC RESISTANCE; BACTERIAL DISEASE; COHORT ANALYSIS; COLONIZATION; DISEASE INCIDENCE; INFECTIOUS DISEASE; SPATIOTEMPORAL ANALYSIS; TEMPORAL PERIOD;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; COMPARATIVE STUDY; CROSS INFECTION; DIAGNOSIS RELATED GROUP; DRUG CONTROL; DRUG EFFECT; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; PRESCRIPTION; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; PUBLIC HOSPITAL; STATISTICS; SUPERINFECTION; UNIVERSITY HOSPITAL; URUGUAY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; CEFTRIAXONE; CIPROFLOXACIN; CROSS INFECTION; DIAGNOSIS-RELATED GROUPS; DRUG AND NARCOTIC CONTROL; DRUG PRESCRIPTIONS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITALS, PUBLIC; HOSPITALS, UNIVERSITY; HUMANS; INCIDENCE; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SUPERINFECTION; URUGUAY;

URUGUAY;

ACINETOBACTER; ACINETOBACTER BAUMANNII; BACILLI (CLASS); NEGIBACTERIA; PSEUDOMONAS AERUGINOSA;

EID: 84859942608     PISSN: 10204989     EISSN: 16805348     Source Type: Journal    
DOI: 10.1590/S1020-49892011001200018     Document Type: Article

References (46)

1. Lorente C, Del Castillo Y, Rello J. Prevention of infection in the intensive care unit: current advances and opportunities for the future. Curr Opin Crit Care. 2002;8(5):461-4.
2. Tenover FC, Hughes JM. The challenges of emerging infectious diseases. Development and spread of multiply-resistant bacterial pathogens. JAMA. 1996;275(4):300-4. (Pubitemid 26028589)
3. Hsueh PR, Teng LJ, Chen CY, Chen WH, Yu CJ, Ho SW, et al. Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerg Infect Dis. 2002;8(8):827-32.
4. Pellegrino FL, Teixeira LM, Carvalho Mda G, Aranha Nouér S, Pinto De Oliveira M, Mello Sampaio JL, et al. Occurrence of a multidrugresistant Pseudomonas aeruginosa clone in different hospitals in Rio de Janeiro, Brazil. J Clin Microbiol. 2002;40(7):2420-4. (Pubitemid 34747341)
5. Coque TM, Oliver A, Pérez-Díaz JC, Baquero F, Cantón R. Genes encoding TEM-4, SHV-2, and CTX-M-10 extended-spectrum betalactamases are carried by multiple Klebsiella pneumoniae clones in a single hospital (Madrid, 1989 to 2000). Antimicrob Agents Chemother. 2002;46(2):500-10. (Pubitemid 34087201)
6. Sanders WE Jr, Sanders CC. Enterobacter spp. pathogens poised to flourish at the turn of the century. Clin Microbiol Rev. 1997;10(2):220-41. (Pubitemid 27196669)
7. Cantón R, Oliver A, Coque TM, Varela M del C, Pérez- Díaz JC, Baquero F. Epidemiology of extended-spectrum beta-lactamase-producing Enterobacter isolates in a Spanish hospital during a 12-year period. J Clin Microbiol. 2002;40(4):1237-43. (Pubitemid 34279882)
8. Oplustil CP, Nunes R, Mendes C, RESISTNET Group. Multicenter evaluation of resistance patterns of Klebsiella pneumoniae, Escherichia coli, Salmonella spp. and Shigella spp. isolated from clinical specimens in Brazil: RESISTNET Surveillance Program. Braz J Infect Dis. 2001;5(1):8-12.
9. Trucco OA, Prado VJ, Durán TM, PRONARES Group. PRONARES antimicrobial surveillance network on antimicrobial agent resistance: report of the first semester 2001. Rev Chil Infect. 2002;19(Suppl 2):S140-8.
10. Sader HS, Jones RN, Gales AC, Silva JB, Pignatari AC, SENTRY Participants Group (Latin America). SENTRY antimicrobial surveillance program report: Latin American and Brazilian results for 1997 through 2001. Braz J Infect Dis. 2004;8(1):25-79.
11. Livermore DM. Beta-lactamases in laboratory and clinical resistance. Clin Microbiol Rev. 1995;8(4):557-84.
12. Massova I, Mobashery S. Kinship and diversification of bacterial penicillin-binding proteins and beta-lactamases. Antimicrob Agents Chemother. 1998;42(1):1-17. (Pubitemid 28053319)
13. Davies J. Inactivation of antibiotics and the dissemination of resistance genes. Science. 1994;264(5157):375-82. (Pubitemid 24178900)
14. Vignoli R, Calvelo E, Cordeiro NF, Lucero R, Ingold E, Quintana A, et al. Association of broad-spectrum antibiotic use with faecal carriage of oxyiminocephalosporin-resistant Enterobacteriaceae in an intensive care unit. J Hosp Infect. 2006;63(3):306-15. (Pubitemid 43812187)
15. Medina J, Formento C, Pontet J, Curbelo A, Bazet C, Gerez J, et al. Prospective study of risk factors for ventilator-associated pneumonia caused by Acinetobacter species. J Crit Care. 2007;22(1):18-26. (Pubitemid 46420755)
16. Garner JS. Guideline for isolation precautions in hospitals. Part I. Evolution of isolation practices, Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1996:24(1):24-31.
17. Shlaes DM, Gerding DN, John JF Jr, Craig WA, Bornstein DL, Duncan RA, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol. 1997;18(4):275-91. (Pubitemid 127470480)
18. Raymond DP, Pelletier SJ, Crabtree TD, Gleason TG, Hamm LL, Pruett TL, et al. Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit. Crit Care Med. 2001;29(6):1101-8. (Pubitemid 32554319)
19. Gruson D, Hilbert G, Vargas F, Valentino R, Bebear C, Allery A, et al. Rotation and restricted use of antibiotics in a medical intensive care unit. Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant Gram-negative bacteria. Am J Respir Crit Care Med. 2000;162(3 Pt 1):837-43.
20. Gruson D, Hilbert G, Vargas F, Valentino R, Bui N, Pereyre S, et al. Strategy of antibiotic rotation: long-term effect on incidence and susceptibilities of Gram-negative bacilli responsible for ventilator-associated pneumonia. Crit Care Med. 2003;31(7):1908-14. (Pubitemid 36900743)
21. Du B, Chen D, Liu D, Long Y, Shi Y, Wang H, et al. Restriction of third-generation cephalosporin use decreases infection-related mortality. Crit Care Med. 2003;31(4):1088-93. (Pubitemid 36444418)
22. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818-29. (Pubitemid 15250137)
23. McCabe WR, Jackson GG. Gram-negative bacteremia. Arch Intern Med. 1962;110(6):847-55.
24. Maxwell M, Heaney D, Howie JG, Noble S. General practice fund holding: observa-tions on prescribing patterns and costs using the defined daily dose method. BMJ. 1993;307(6913):1190-4. (Pubitemid 23319341)
25. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32(8):470-85.
26. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Eleventh informational supplement NCCLS M100-S11. Wayne, Pennsylvania: Clinical and Laboratory Standards Institute; 2001.
27. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16(3):128-40.
28. Flanagan P, Findlay G, Magee J, Ionescu A, Barnes RA, Smithies M. The diagnosis of ventilator-associated pneumonia using nonbronchoscopic, non-directed lung lavages. Intensive Care Med. 2000;26(1):20-30. (Pubitemid 30184456)
29. Montravers P, Fagon JY, Chastre J, Lecso M, Dombret MC, Trouillet JL, et al. Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia. Am Rev Respir Dis. 1993;147(1):38-44. (Pubitemid 23025912)
30. Bergmans DC, Bonten MJ, De Leeuw PW, Stobberingh EE. Reproducibility of quantitative cultures of endotracheal aspirates from mechanically ventilated patients. J Clin Microbiol. 1997;35(3):796-8. (Pubitemid 27083889)
31. Ortega B, Groeneveld AB, Schultsz C. Endemic multidrug-resistant Pseudomonas aeruginosa in critically ill patients. Infect Control Epidemiol. 2004;25(10):825-31. (Pubitemid 40036757)
32. Murthy R. Implementation of strategies to control antimicrobial resistance. Chest. 2001; 119(2 Suppl):405S-11S. (Pubitemid 32163810)
33. Raymond DP, Pelletier SJ, Crabtree TD, Evans HL, Pruett TL, Sawyer RG. Impact of antibiotic-resistant Gram-negative bacilli infections on outcome in hospitalized patients. Crit Care Med. 2003;31(4):1035-41. (Pubitemid 36444410)
34. Baumgartner JD, Glauser MP. Pharmacokinetic and microbial susceptibility studies of ceftriaxone. Eur J Clin Microbiol. 1983;2(5):501-4. (Pubitemid 14238286)
35. Patel IH, Chen S, Parsonnet M, Hackman MR, Brooks MA, Konikoff J, et al. Pharmacokinetics of ceftriaxone in humans. Antimicrob Agents Chemother. 1981;20(5):634-41. (Pubitemid 12168041)
36. Corbella X, Pujol M, Ayats J, Sendra M, Ardanuy C, Domínguez MA, et al. Relevance of digestive tract colonization in the epidemiology of nosocomial infections due to multiresistant Acinetobacter baumannii. Clin Infect Dis. 1996;23(2):329-34. (Pubitemid 26264917)
37. Aubert G, Carricajo A, Vautrin AC, Guyomarc'h S, Fonsale N, Page D, et al. Impact of restricting fluoroquinolone prescription on bacterial resistance in an intensive care unit. J Hosp Infect. 2005;59(2):83-9. (Pubitemid 40058032)
38. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among Gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA. 2003;289(7): 885-8. (Pubitemid 37430348)
39. Friedland I, Gallagher G, King T, Woods GL. Antimicrobial susceptibility patterns in Pseudomonas aeruginosa: data from a multicenter Intensive Care Unit Surveillance Study (ISS) in the United States. J Chemother. 2004;16(5):437-41. (Pubitemid 39491069)
40. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999;115(2):462-74. (Pubitemid 29083057)
41. Paterson DL. Restrictive antibiotic policies are appropriate in intensive care units. Crit Care Med. 2003;31(Suppl):S25-8. (Pubitemid 36143474)
42. Archibald LK, Manning ML, Bell LM, Banerjee S, Jarvis WR. Patient density, nurse-to-patient ratio and nosocomial infection risk in a pediatric cardiac intensive care unit. Pediatr Infect Dis J. 1997;16(11):1045-8. (Pubitemid 27494961)
43. Robert J, Fridkin SK, Blumberg HM, Anderson B, White N, Ray SM, et al. The influence of the composition of the nursing staff on primary bloodstream infection rates in a surgical intensive care unit. Infect Control Hosp Epidemiol. 2000;21(1):12-7.
44. Bado I, Cordeiro NF, Robino L, García-Fulqueiras V, Seija V, Bazet C, et al. Detection of class 1 and 2 integrons, extended-spectrum β-lactamases and qnr alleles in enterobacterial isolates from the digestive tract of intensive care unit inpatients. Int J Antimicrob Agents. 2010;36(5):453-8.
45. Rahal JJ, Urban C, Horn D, Freeman K, Segal-Maurer S, Maurer J, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA. 1998;280(14):1233-7. (Pubitemid 28469228)
46. Bantar C, Curcio D, Jasovich A, Bagnulo H, Arango A, Bavestrello L, et al. Neumonía aguda adquirida en la comunidad en adultos: actualización de los lineamientos para el tratamiento antimicrobiano inicial basado en la evidencia local del Grupo de Trabajo de Sudamérica (ConsenSur II). Rev Chilena Infectol. 2010;27(Suppl 1):S9-38.